Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 11/20 | 0.43 |
| ▸ | SCTR | P47872 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | GRPR | P30550 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3125104 | 1.00 | GLP1R (0.43) | GLP1RSCTROPRD1OPRM1OPRK1 | |
| SCHEMBL2465543 | 0.92 | GLP1R (0.50) | GLP1RSCTROPRD1OPRM1OPRK1 | |
| SCHEMBL677186 | 0.92 | GLP1R (0.45) | GLP1RSCTROPRD1OPRM1OPRK1 | |
| SCHEMBL676444 | 0.89 | GLP1R (0.47) | GLP1RSCTR | |
| SCHEMBL29375435 | 0.89 | GLP1R (0.51) | GLP1RSCTROPRD1OPRM1OPRK1 | |
| SCHEMBL31253154 | 0.87 | GLP1R (0.45) | GLP1RSCTROPRD1OPRM1OPRK1 | |
| SCHEMBL677433 | 0.87 | GLP1R (0.43) | GLP1RSCTROPRD1OPRM1OPRK1 | |
| SCHEMBL30124627 | 0.87 | GLP1R (0.40) | GLP1RSCTROPRD1OPRM1OPRK1 | |
| SCHEMBL31741239 | 0.85 | GLP1R (0.55) | GLP1RSCTR | |
| SCHEMBL2468098 | 0.85 | GLP1R (0.50) | GLP1RSCTROPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | GLP1R 33/4885SCTR 1216/4885OPRD1 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.